POINT Biopharma Provides Early-Stage Program Updates

POINT Biopharma Global Inc. (“POINT”), a company engaged in the development, and global access to life-changing radiopharmaceuticals, provided progress updates on its early-stage programs below, including the pan-cancer fibroblast activation protein-alpha (FAP-alpha) inhibitor program PNT2004, and the next-generation actinium-225PSMA targeted program PNT2001.

PNT2004 (FAP-alpha inhibitor): Initiation of a Phase 1 therapeutic dose-escalating clinical trial is planned for summer 2022. POINT accelerated PNT2004’s therapeutic program after the compelling preclinical data for PNT2004’s lead candidate PNT6555 was first announced in Q4 of 2021.

The clinical trial is expected to commence in this summer in Canada and will use a gallium-68 (Ga-68)-based PNT6555 molecular imaging agent to select patients to receive a no-carrier-added (n.c.a.) lutetium-177(Lu-177)-based PNT6555 therapeutic agent. Additional preclinical studies in syngeneic and PDX models for monotherapy and combination treatment are in development and include other therapeutic isotopes such as actinium-225 (Ac-225).

PNT2001 (Next generation PSMA): IND-enabling studies with actinium-225 are planned for 2022. IND/CTA filing is expected in the first half of 2023.

The PNT2001 program leverages linker technology that promotes increased tumor accumulation. Pre-clinical studies of PNT2001 have resulted in the identification of a lead candidate which, as compared to late-stage PSMA ligands, demonstrates potent anti-tumor activity using Ac-225, while also having an improved safety profile. The Company has advanced the lead candidate into IND-enabling studies which are expected to support an IND/CTA submission in he first half of 2023.

To read more please visit:

https://www.pointbiopharma.com/press-releases/early-stage-program-updates

Source: POINT